In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY

• https://twitter.com/synovialjoints/status/1801180459742671358/photo/1
• https://twitter.com/synovialjoints/status/1801180459742671358/photo/1

OP0072 @RheumNow #EULAR2024 Effects of #Upadacitinib or #Adalimumab on pain in #RA SELECT-COMPARE Phase 3 study UPA & ADA led to improvements in pain vs PBO PtGA & TJC28 pain improvement similar between UPA & ADA ➡️ UPA may be more effective in control of pain than ADA in RA

More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ) Somewhat reassuring post-ORAL Surveillance infection data #EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2

• https://twitter.com/drdavidliew/status/1800922236372791605/photo/1

Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

• https://twitter.com/synovialjoints/status/1800915408175927352/photo/1

A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb

• https://twitter.com/i/web/status/1800905811591307533
• https://twitter.com/synovialjoints/status/1800905811591307533/photo/1

Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24

OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024